Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MCLENA-1: Lenalidomide in Mild Cognitive Impairment Due to Alzheimer's Disease
NCT04032626Phase 2Completed
- Sponsor
- St. Joseph's Hospital and Medical Center
- Start
- Jul 2020
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lenalidomide in Alzheimer's disease (AD), sponsored by St. Joseph's Hospital and Medical Center. Started Jul 2020; status: completed.
02
Drugs
lenalidomide
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT04032626.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04032626.